Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

Table 3 Univariate analysis of baseline predictors of 52-wk survival n (%)

Group	Survivors (n = 68)	Non-survivors (n = 51)	t/χ2/z	P value
Age (yr)	39.4 ± 11.7	43.2 ± 9.9	1.871	0.064
Males	38 (55.9)	39 (76.5)	5.409	0.020
Platelet count (103/μL)	93.5 ± 38.2	87.3 ± 34.1	0.917	0.361
ALT level (U/L)	367.3 ± 80.4	345.0 ± 72.6	1.560	0.121
HBeAg-positive	20 (29.4)	24 (47.1)	3.895	0.048
HBV DNA (log10 copies/mL)	7.2 ± 1.4	6.9 ± 1.5	1.122	0.264
HBV DNA undetectable (< 103 copies/mL)
Day 15	3 (4.4)	0 (0.0)	2.309	0.129
Day 30	17 (25.0)	5 (9.8)	4.466	0.035
Day 45	20 (29.4)	9 (17.6)	2.189	0.139
Day 60	21 (30.9)	12 (23.5)	1.020	0.313
Treatment with entecavir	42(61.8)	23 (45.1)	3.266	0.071
CTP points (> 10/< 10)	30/38	33/18	4.958	0.026
MELD points (> 25/< 25)	28/40	32/19	5.423	0.020

All values are expressed as mean ± SD or number (%). ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; CTP: Child-Turcotte Pugh; MELD: Model for end-stage liver disease.